SCHEMBL8409262

SCHEMBL8409262

CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 6/20 0.67
CYP3A4 P08684 2/20 0.67
PGR P06401 1/20 0.67
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.50
HTT P42858 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GPR55 Q9Y2T6 1/20 0.50
PPIA P62937 1/20 0.48
ABCC9 O60706 1/20 0.47
ABCC8 Q09428 1/20 0.47
KCNJ11 Q14654 1/20 0.47
KCNJ8 Q15842 1/20 0.47
GAA P10253 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8407131 0.89 AR (0.53) ARCYP3A4PGRLMNAMAPT
SCHEMBL10975838 0.87 ABCC9 (0.64) ARCYP3A4PGRABCC9ABCC8
SCHEMBL27630726 0.84 AR (0.69) ARCYP3A4PGRLMNAMAPT
SCHEMBL8407500 0.83 MAPT (0.50) ARCYP3A4PGRLMNAMAPT
SCHEMBL8407245 0.83 AR (0.67) ARCYP3A4PGRHTTABCC9
SCHEMBL8407369 0.83 AR (0.71) ARCYP3A4PGRLMNAMAPT
SCHEMBL8407128 0.82 AR (0.57) ARCYP3A4PGRLMNAMAPT
SCHEMBL358946 0.82 HTT (0.61) LMNAMAPTHTTPPIAGAA
SCHEMBL31171019 0.82 HTT (0.61) LMNAMAPTHTTPPIAGAA
SCHEMBL10421023 0.82 AR (0.52) ARCYP3A4PGRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5994362-A ADMINISTERING FINASTERIDE AND CASODEX MERCK & CO., INC. (US) 1999-11-30 US disclosed
EP-0514056-A2 Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry MERCK & CO. INC. (US) 1992-11-19 EP disclosed
WO-1992016233-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO disclosed